Infovista Launches 5G NR Network Planning and Testing Solutions
31.10.2018 15:00:00 EET | Business Wire | Press release
Infovista, the leader in modern network performance, today announced the latest version of TEMS Investigation. This new version is designed to provide Mobile Network Operators, Infrastructure vendors and Regulators with the ability to clear 5G spectrum, accurately measure the 5G NR network coverage, and provide input for 5G NR propagation model tuning.
TEMS Network Testing software can now be used together with commercial 5G NR Scanner Receivers. Infovista has been testing this solution in the field, in a number of 5G NR network trials with tier 1 operators and with several global infrastructure suppliers. The equipment has been used together with Infovista Planet, to accurately tune 5G NR propagation models (both Sub 6Ghz and mmWave)
With initial support of PCTel and plans for agnostic scanner support, customers will be able to choose between different scanners types and models to support both standalone (SA) and non-standalone (NSA) 5G NR network testing. The software can either run on a laptop or on a PC clustered solution. Both solutions can be controlled centrally by Infovista’s orchestration and real time analytics tool, TEMS Director. TEMS Director includes Network Analytics based on Artificial Intelligence and Machine Learning, which can reduce the operating costs of drive-testing by up to 60%.
Both TEMS Investigation and TEMS Paragon are designed to use commercial 5G NR devices as they become available. This will allow early adopters of 5G NR to gain insight into the performance of different smartphones and their interaction with real 5G NR networks. Today, Infovista is the only vendor with 5G planning, geodata and Network Testing capability.
“With nearly 300 mobile operators announcing 5G rollout plans or trials in the near future, the need for accurate network planning and testing will be pivotal to the future success of 5G services,” said Adrian Jakobsson, SVP RAN portfolio. “By providing the tools to develop and test accurate 5G propagation models, we plan to help our customers deliver the highest quality and most efficient 5G network deployments in their respective markets.”
For more information on Infovista TEMS Investigation solutions, visit: https://www.infovista.com/products/tems-portfolio.
About Infovista
Infovista, the leader in modern network performance, provides complete visibility and unprecedented control over modern networks and their applications. Infovista delivers brilliant user experiences and maximum value for networks and applications. At the core of its approach are data and analytics, to give service providers and enterprises real-time insights to make critical business decisions. Infovista offers a comprehensive line of solutions from the radio network to enterprise to device throughout the lifecycle of a network. No other solutions provider has this totality of vision. More than 1,500 enterprises and service providers around the world—including 250 of the world’s top mobile network operators—rely on Infovista. Know Your Network with Infovista.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005052/en/
Contact information
Infovista
Henry Chalian, 703-707-1742
Henry.chalian@infovista.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom